Data from Pharmawand - Curated by Toby Galbraith - Date added 12 October 2017
Lupin has announced that its US subsidiary, Lupin, Inc., has acquired Symbiomix Therapeutics, LLC. Lupin had entered into an option to acquire the company earlier this year. Symbiomix is a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. The acquisition has been made for a cash consideration of $ 150 million including a $50 million upfront and other time-based payments. In addition, there are sales based contingent payments.
The transaction is now closed. The acquisition of Symbiomix and the Solosec franchise significantly expands Lupin’s branded women’s health specialty business, which is presently anchored by Methergine (methylergonovine) tablets.
Comment: The FDA approved Symbiomix’s lead product, Solosec (secnidazole) oral granules in September 2017, for the treatment of bacterial vaginosis (BV) in adult women. Lupin expects Solosec to be commercially available by mid-2018. Solosec was designated as a Qualified Infectious Disease Product (QIDP) by the FDA for the treatment of BV. QIDP designation is for medications intended to treat serious or life-threatening infections and makes Solosec eligible for at least 10 years of exclusivity in the United States.